Abstract
This economic evaluation study estimates the potential Medicare savings from generic substitution and therapeutic interchange of brand-name hypertension medications.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiotensin Receptor Antagonists / economics
-
Angiotensin Receptor Antagonists / therapeutic use*
-
Angiotensin-Converting Enzyme Inhibitors / economics
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
-
Antihypertensive Agents / economics
-
Antihypertensive Agents / therapeutic use*
-
Cost Savings
-
Drug Substitution / economics*
-
Drugs, Generic / economics
-
Drugs, Generic / therapeutic use*
-
Humans
-
Hypertension / drug therapy*
-
Medicare
-
United States
Substances
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Drugs, Generic